Plain-English translation of NCT06465537 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing BD113vVLP, a new gene-editing treatment designed to help people with primary open-angle glaucoma (a common type of glaucoma) who have a mutation in the MYOC gene. You would receive a single injection of this medication directly into your eye. The researchers will then monitor your eye pressure and vision over one year to see if the treatment is safe and effective.
Some patients with glaucoma don't respond well enough to eye drops or other standard medications, and their eye pressure stays dangerously high, which can lead to vision loss. This trial is exploring whether fixing the underlying gene mutation with gene-editing technology might offer a new way to lower eye pressure and protect vision.
You likely qualify if…
You likely don't qualify if…
You would come to the clinic for a screening visit to confirm you qualify. If you do, you would receive a single injection of the medication directly into your eye. Over the next year, you would have regular follow-up visits to check your eye pressure, vision, and overall eye health, and to look for any side effects. Blood tests and eye exams will be part of your monitoring.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China